Tags

Type your tag names separated by a space and hit enter

A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency.
J Womens Health (Larchmt) 2012; 21(6):674-82JW

Abstract

BACKGROUND

S-equol, a metabolite of the soy isoflavone daidzein, has been proposed as having potential for relief of menopausal symptoms. This study compared the efficacy of the natural S-equol supplement, SE5-OH, with isoflavones for relieving hot flashes and other menopausal symptoms.

METHODS

An 8-week randomized, double-blind, active comparator trial with SE5-OH was conducted in postmenopausal women (aged 45-65 years), who experienced ≥5 hot flashes/day. Participants (n=102) were assigned to one of four treatment groups: 10 (n=24), 20 (n=27), or 40 (n=25) mg S-equol/day or soy isoflavones (n=26). Participants recorded their hot flash frequency and rated their menopause symptom severity.

RESULTS

Reductions in hot flash frequency at week 8 were similar for all treatment groups. However, based on analyses of the cumulative effect for the 8-week period, 40 mg/day S-equol had a greater reduction of hot flash frequency compared to isoflavones (p=0.021). A subgroup analysis further indicated that for subjects with >8 hot flashes/day at baseline, 20 and 40 mg/day S-equol were superior to isoflavones in reducing hot flash frequency (p=0.045 and p=0.001, respectively). In addition, 10 and 20 mg/day S-equol improved muscle and joint pain score compared with isoflavones (p=0.003 and p=0.005, respectively).

CONCLUSIONS

S-equol, 10 mg/day, appears to be as effective as soy isoflavones at reducing hot flash frequency and more effective for relieving muscle and joint pain in postmenopausal women. S-equol, ≥20 mg/day, alleviates hot flashes to a greater extent than soy isoflavones in those women who experience >8 hot flashes/day.

Authors+Show Affiliations

Pharmavite LLC, Northridge, CA 91604, USA. bjenks@pharmavite.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22409590

Citation

Jenks, Belinda H., et al. "A Pilot Study On the Effects of S-equol Compared to Soy Isoflavones On Menopausal Hot Flash Frequency." Journal of Women's Health (2002), vol. 21, no. 6, 2012, pp. 674-82.
Jenks BH, Iwashita S, Nakagawa Y, et al. A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency. J Womens Health (Larchmt). 2012;21(6):674-82.
Jenks, B. H., Iwashita, S., Nakagawa, Y., Ragland, K., Lee, J., Carson, W. H., ... Uchiyama, S. (2012). A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency. Journal of Women's Health (2002), 21(6), pp. 674-82. doi:10.1089/jwh.2011.3153.
Jenks BH, et al. A Pilot Study On the Effects of S-equol Compared to Soy Isoflavones On Menopausal Hot Flash Frequency. J Womens Health (Larchmt). 2012;21(6):674-82. PubMed PMID: 22409590.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency. AU - Jenks,Belinda H, AU - Iwashita,Soh, AU - Nakagawa,Yasushi, AU - Ragland,Karen, AU - Lee,Jennifer, AU - Carson,William H, AU - Ueno,Tomomi, AU - Uchiyama,Shigeto, Y1 - 2012/03/12/ PY - 2012/3/14/entrez PY - 2012/3/14/pubmed PY - 2012/9/21/medline SP - 674 EP - 82 JF - Journal of women's health (2002) JO - J Womens Health (Larchmt) VL - 21 IS - 6 N2 - BACKGROUND: S-equol, a metabolite of the soy isoflavone daidzein, has been proposed as having potential for relief of menopausal symptoms. This study compared the efficacy of the natural S-equol supplement, SE5-OH, with isoflavones for relieving hot flashes and other menopausal symptoms. METHODS: An 8-week randomized, double-blind, active comparator trial with SE5-OH was conducted in postmenopausal women (aged 45-65 years), who experienced ≥5 hot flashes/day. Participants (n=102) were assigned to one of four treatment groups: 10 (n=24), 20 (n=27), or 40 (n=25) mg S-equol/day or soy isoflavones (n=26). Participants recorded their hot flash frequency and rated their menopause symptom severity. RESULTS: Reductions in hot flash frequency at week 8 were similar for all treatment groups. However, based on analyses of the cumulative effect for the 8-week period, 40 mg/day S-equol had a greater reduction of hot flash frequency compared to isoflavones (p=0.021). A subgroup analysis further indicated that for subjects with >8 hot flashes/day at baseline, 20 and 40 mg/day S-equol were superior to isoflavones in reducing hot flash frequency (p=0.045 and p=0.001, respectively). In addition, 10 and 20 mg/day S-equol improved muscle and joint pain score compared with isoflavones (p=0.003 and p=0.005, respectively). CONCLUSIONS: S-equol, 10 mg/day, appears to be as effective as soy isoflavones at reducing hot flash frequency and more effective for relieving muscle and joint pain in postmenopausal women. S-equol, ≥20 mg/day, alleviates hot flashes to a greater extent than soy isoflavones in those women who experience >8 hot flashes/day. SN - 1931-843X UR - https://www.unboundmedicine.com/medline/citation/22409590/A_pilot_study_on_the_effects_of_S_equol_compared_to_soy_isoflavones_on_menopausal_hot_flash_frequency_ L2 - https://www.liebertpub.com/doi/full/10.1089/jwh.2011.3153?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -